Tags

Type your tag names separated by a space and hit enter

A triple therapy regimen after failed Helicobacter pylori treatments.
Aliment Pharmacol Ther 2001; 15(8):1193-7AP

Abstract

BACKGROUND

Following standard triple therapy, up to 20% of patients require further Helicobacter pylori eradication treatment. Data regarding the efficacy of re-treatment in these patients are scarce.

AIM

To evaluate the efficacy of a triple therapy after one or more consecutive treatment failures.

METHODS

A total of 51 patients with persistent H. pylori infection after at least one unsuccessful standard 1-week regimen were enrolled in the study. H. pylori infection at entry was assessed by rapid urease test and histology on biopsies from the antrum and the corpus. Patients were given a 2-week triple therapy, comprising ranitidine bismuth citrate 400 mg b.d., tetracycline 500 mg t.d.s., and tinidazole 500 mg b.d. Ranitidine bismuth citrate was given during meals, whilst tetracycline and tinidazole was given after meals. Bacterial eradication was assessed by endoscopy (36 patients) or 13C-urea breath test (15 patients) 4-6 weeks after therapy had ended.

RESULTS

All 51 patients completed the study and H. pylori eradication was achieved in 46, with an eradication rate of 90% (95% CI: 82-98). In detail, bacterial eradication was obtained in 96% of patients who had previously failed one course of clarithromycin-amoxicillin based triple therapy, in 88% patients who had failed a clarithromycin-tinidazole based triple therapy, in 83% patients who had failed both treatment schedules, and in the only patient who had failed three consecutive therapeutic attempts. Two patients took the therapy for 9 and 10 days instead of the full 14 day-course. No major side-effects were reported, whilst six (12%) patients complained of mild side-effects.

CONCLUSION

This study demonstrates that this triple therapy regimen is effective for re-treatment of H. pylori infection.

Authors+Show Affiliations

Gastroenterology and Digestive Endoscopy, 'Nuovo Regina Margherita' Hospital, Rome, Italy. zullo@tiscalinet.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

11472322

Citation

Zullo, A, et al. "A Triple Therapy Regimen After Failed Helicobacter Pylori Treatments." Alimentary Pharmacology & Therapeutics, vol. 15, no. 8, 2001, pp. 1193-7.
Zullo A, Hassan C, Campo SM, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther. 2001;15(8):1193-7.
Zullo, A., Hassan, C., Campo, S. M., Lorenzetti, R., Febbraro, I., De Matthaeis, M., ... Morini, S. (2001). A triple therapy regimen after failed Helicobacter pylori treatments. Alimentary Pharmacology & Therapeutics, 15(8), pp. 1193-7.
Zullo A, et al. A Triple Therapy Regimen After Failed Helicobacter Pylori Treatments. Aliment Pharmacol Ther. 2001;15(8):1193-7. PubMed PMID: 11472322.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A triple therapy regimen after failed Helicobacter pylori treatments. AU - Zullo,A, AU - Hassan,C, AU - Campo,S M, AU - Lorenzetti,R, AU - Febbraro,I, AU - De Matthaeis,M, AU - Porto,D, AU - Morini,S, PY - 2001/7/27/pubmed PY - 2002/1/5/medline PY - 2001/7/27/entrez SP - 1193 EP - 7 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 15 IS - 8 N2 - BACKGROUND: Following standard triple therapy, up to 20% of patients require further Helicobacter pylori eradication treatment. Data regarding the efficacy of re-treatment in these patients are scarce. AIM: To evaluate the efficacy of a triple therapy after one or more consecutive treatment failures. METHODS: A total of 51 patients with persistent H. pylori infection after at least one unsuccessful standard 1-week regimen were enrolled in the study. H. pylori infection at entry was assessed by rapid urease test and histology on biopsies from the antrum and the corpus. Patients were given a 2-week triple therapy, comprising ranitidine bismuth citrate 400 mg b.d., tetracycline 500 mg t.d.s., and tinidazole 500 mg b.d. Ranitidine bismuth citrate was given during meals, whilst tetracycline and tinidazole was given after meals. Bacterial eradication was assessed by endoscopy (36 patients) or 13C-urea breath test (15 patients) 4-6 weeks after therapy had ended. RESULTS: All 51 patients completed the study and H. pylori eradication was achieved in 46, with an eradication rate of 90% (95% CI: 82-98). In detail, bacterial eradication was obtained in 96% of patients who had previously failed one course of clarithromycin-amoxicillin based triple therapy, in 88% patients who had failed a clarithromycin-tinidazole based triple therapy, in 83% patients who had failed both treatment schedules, and in the only patient who had failed three consecutive therapeutic attempts. Two patients took the therapy for 9 and 10 days instead of the full 14 day-course. No major side-effects were reported, whilst six (12%) patients complained of mild side-effects. CONCLUSION: This study demonstrates that this triple therapy regimen is effective for re-treatment of H. pylori infection. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/11472322/A_triple_therapy_regimen_after_failed_Helicobacter_pylori_treatments_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2001&volume=15&issue=8&spage=1193 DB - PRIME DP - Unbound Medicine ER -